Zhenyang Liang

548 total citations
16 papers, 301 citations indexed

About

Zhenyang Liang is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Zhenyang Liang has authored 16 papers receiving a total of 301 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Cardiology and Cardiovascular Medicine, 7 papers in Internal Medicine and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Zhenyang Liang's work include Acute Myocardial Infarction Research (8 papers), Venous Thromboembolism Diagnosis and Management (7 papers) and Antiplatelet Therapy and Cardiovascular Diseases (6 papers). Zhenyang Liang is often cited by papers focused on Acute Myocardial Infarction Research (8 papers), Venous Thromboembolism Diagnosis and Management (7 papers) and Antiplatelet Therapy and Cardiovascular Diseases (6 papers). Zhenyang Liang collaborates with scholars based in China, United States and Australia. Zhenyang Liang's co-authors include Yaling Han, Yi Li, Gregg W. Stone, Jing Li, Xin Zhao, Chenghui Yan, Quanmin Jing, Haiwei Liu, Yu Wang and Xi Su and has published in prestigious journals such as JAMA, SHILAP Revista de lepidopterología and Clinica Chimica Acta.

In The Last Decade

Zhenyang Liang

14 papers receiving 297 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zhenyang Liang China 6 249 144 111 22 18 16 301
Prospero Gogo United States 9 218 0.9× 36 0.3× 163 1.5× 11 0.5× 9 0.5× 14 266
Loukas Sinos Greece 4 275 1.1× 51 0.4× 61 0.5× 19 0.9× 6 0.3× 5 330
Shigeru Amitani Japan 7 352 1.4× 112 0.8× 58 0.5× 10 0.5× 12 0.7× 17 396
Francisco Cambronero Spain 6 271 1.1× 46 0.3× 52 0.5× 23 1.0× 4 0.2× 9 312
E. Hamodraka Greece 8 319 1.3× 37 0.3× 65 0.6× 20 0.9× 11 0.6× 9 404
Katarzyna Ptaszyńska‐Kopczyńska Poland 10 146 0.6× 43 0.3× 35 0.3× 35 1.6× 18 1.0× 25 258
Farhan Shahid United Kingdom 10 303 1.2× 25 0.2× 53 0.5× 39 1.8× 22 1.2× 40 400
Alexander Joost Germany 8 233 0.9× 45 0.3× 182 1.6× 8 0.4× 4 0.2× 15 308
Rafael Cobas Paz Spain 8 199 0.8× 36 0.3× 41 0.4× 4 0.2× 7 0.4× 23 236
Ahmet Güner Türkiye 9 167 0.7× 28 0.2× 83 0.7× 10 0.5× 32 1.8× 60 243

Countries citing papers authored by Zhenyang Liang

Since Specialization
Citations

This map shows the geographic impact of Zhenyang Liang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhenyang Liang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhenyang Liang more than expected).

Fields of papers citing papers by Zhenyang Liang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhenyang Liang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhenyang Liang. The network helps show where Zhenyang Liang may publish in the future.

Co-authorship network of co-authors of Zhenyang Liang

This figure shows the co-authorship network connecting the top 25 collaborators of Zhenyang Liang. A scholar is included among the top collaborators of Zhenyang Liang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhenyang Liang. Zhenyang Liang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Li, Yang, Zhenyang Liang, Yi Li, et al.. (2025). Ticagrelor vs. clopidogrel in bivalirudin-treated patients with STEMI undergoing primary PCI: The BRIGHT-4 trial. Cardiovascular revascularization medicine. 83. 10–16.
2.
Liao, Jia, Miaohan Qiu, Xiaojian Feng, et al.. (2024). Bivalirudin versus heparin in patients with or without bail-out GPI use: a pre-specified subgroup analysis from the BRIGHT-4 trial. BMC Medicine. 22(1). 410–410. 1 indexed citations
3.
Liang, Zhenyang, et al.. (2024). Snare Assistance Technique for Difficult Aortic Valve Crossing During TAVR. JACC: Cardiovascular Interventions. 17(10). 1289–1291.
4.
Liu, Xian, Yingdong Wang, Yaling Han, et al.. (2023). Neo-Commissural Alignment by Withdrawing and Readvancing the Delivery System during Transcatheter Aortic Valve Replacement with Self-Expanding Prosthesis. Journal of Interventional Cardiology. 2023. 1–6. 1 indexed citations
5.
6.
Li, Yi, Chenghui Yan, Xiaolin Zhang, et al.. (2022). Clonal hematopoiesis of indeterminate potential in patients with acute coronary syndrome undergoing percutaneous coronary intervention in the absence of traditional risk factors. Clinical Research in Cardiology. 112(4). 506–517. 10 indexed citations
7.
8.
9.
10.
Liang, Zhenyang, Jingping Wang, Dongmei Wang, et al.. (2016). The safety and effectiveness of bivalirudin in female patients with acute myocardial infarction undergoing primary angioplasty: A subgroup analysis of the BRIGHT trial. Catheterization and Cardiovascular Interventions. 87(S1). 608–615. 8 indexed citations
11.
Zhang, Xiaolin, et al.. (2015). Chemokine CX3CL1 and its receptor CX3CR1 are associated with human atherosclerotic lesion volnerability. Thrombosis Research. 135(6). 1147–1153. 26 indexed citations
12.
Han, Yaling, Jincheng Guo, Yang Zheng, et al.. (2015). Bivalirudin vs Heparin With or Without Tirofiban During Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction. JAMA. 313(13). 1336–1336. 193 indexed citations
13.
14.
Li, Yi, Zhidong Li, Xiaolin Zhang, et al.. (2012). Association of ALOX5AP haplotypes with susceptibility to coronary artery disease in a Chinese Han population. European Journal of Internal Medicine. 23(5). e119–e123. 5 indexed citations
15.
Liang, Zhenyang, Xiaolin Zhang, Jing Bai, et al.. (2010). Association of interleukin-6 gene -572C/G single nucleotide polymorphism with coronary artery disease in Han population of north China.. Xiandai shengwu yixue jinzhan. 10(24). 4675–4678. 2 indexed citations
16.
Wang, Tao, Mingxiang Zhang, Yaling Han, et al.. (2010). Lack of association between cellular repressor of E1A-stimulated genes (GREG) polymorphisms and coronary artery disease in the Han population of North China. Clinica Chimica Acta. 412(3-4). 249–252. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Prospero Gogo Breakdown of academic impact, for papers by Loukas Sinos Breakdown of academic impact, for papers by Shigeru Amitani Breakdown of academic impact, for papers by Francisco Cambronero Breakdown of academic impact, for papers by E. Hamodraka Breakdown of academic impact, for papers by Katarzyna Ptaszyńska‐Kopczyńska Breakdown of academic impact, for papers by Farhan Shahid Breakdown of academic impact, for papers by Alexander Joost Breakdown of academic impact, for papers by Rafael Cobas Paz Breakdown of academic impact, for papers by Ahmet Güner
Rankless by CCL
2026